Shipping to United Kingdom We Offer Worldwide Shipping
Login Wishlist

Sterebin E


  • Brand : BIOFRON

  • Catalogue Number : BD-P0414

  • Specification : 95.0%(HPLC)

  • CAS number : 114343-74-7

  • Formula : C20H34O4

  • Molecular Weight : 338.482

  • Volume : 5mg

Available on backorder

Checkout Bulk Order?

Catalogue Number


Analysis Method






Molecular Weight




Botanical Source

Structure Type











Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc.

Flash Point

Boiling Point

Melting Point



InChl Key


WGK Germany


HS Code Reference


Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:114343-74-7) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

No Technical Documents Available For This Product.




Epithelial ovarian cancer (EOC) has a heritable component that remains to be fully characterized. Most identified common susceptibility variants lie in non-protein-coding sequences. We hypothesized that variants in the 3′ untranslated region at putative microRNA (miRNA) binding sites represent functional targets that influence EOC susceptibility. Here, we evaluate the association between 767 miRNA binding site single nucleotide polymorphisms (miRSNPs) and EOC risk in 18,174 EOC cases and 26,134 controls from 43 studies genotyped through the Collaborative Oncological Gene-environment Study. We identify several miRSNPs associated with invasive serous EOC risk (OR=1.12, P=10−8) mapping to an inversion polymorphism at 17q21.31. Additional genotyping of non-miRSNPs at 17q21.31 reveals stronger signals outside the inversion (P=10−10). Variation at 17q21.31 associates with neurological diseases, and our collaboration is the first to report an association with EOC susceptibility. An integrated molecular analysis in this region provides evidence for ARHGAP27 and PLEKHM1 as candidate EOC susceptibility genes.


Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31


Jennifer Permuth-Wey,1,* Kate Lawrenson,2,* Howard C. Shen,2,* Aneliya Velkova,1 Jonathan P. Tyrer,3 Zhihua Chen,4 Hui-Yi Lin,5 Y. Ann Chen,5 Ya-Yu Tsai,1 Xiaotao Qu,4 Susan J. Ramus,2 Rod Karevan,2 Janet Lee,2 Nathan Lee,2 Melissa C. Larson,6 Katja K. Aben,7,8 Hoda Anton-Culver,9 Natalia Antonenkova,10 Antonis Antoniou,11 Sebastian M. Armasu,6 Australian Cancer Study,12 Australian Ovarian Cancer Study,12,13 Francois Bacot,14 Laura Baglietto,15,16 Elisa V. Bandera,17 Jill Barnholtz-Sloan,18 Matthias W. Beckmann,19 Michael J. Birrer,20 Greg Bloom,4 Natalia Bogdanova,21 Louise A. Brinton,22 Angela Brooks-Wilson,23 Robert Brown,24 Ralf Butzow,25,26 Qiuyin Cai,27 Ian Campbell,13,28 Jenny Chang-Claude,29 Stephen Chanock,22 Georgia Chenevix-Trench,12 Jin Q. Cheng,30 Mine S. Cicek,31 Gerhard A. Coetzee,32 Consortium of Investigators of Modifiers of BRCA1/2,33,34 Linda S. Cook,35 Fergus J. Couch,34 Daniel W. Cramer,36 Julie M. Cunningham,31 Agnieszka Dansonka-Mieszkowska,37 Evelyn Despierre,38 Jennifer A Doherty,39 Thilo Dork,21 Andreas du Bois,40,41 Matthias Durst,42 Douglas F Easton,11,43 Diana Eccles,44 Robert Edwards,45 Arif B. Ekici,46 Peter A. Fasching,19,47 David A. Fenstermacher,4 James M. Flanagan,24 Montserrat Garcia-Closas,48 Aleksandra Gentry-Maharaj,49 Graham G. Giles,15,16,50 Rosalind M. Glasspool,51 Jesus Gonzalez-Bosquet,52 Marc T. Goodman,53 Martin Gore,54 Bohdan Gorski,55 Jacek Gronwald,55 Per Hall,56 Mari K. Halle,57,58 Philipp Harter,40,41 Florian Heitz,40,41 Peter Hillemanns,59 Maureen Hoatlin,60 Claus K. Høgdall,61 Estrid Høgdall,62,63 Satoyo Hosono,64 Anna Jakubowska,55 Allan Jensen,63 Heather Jim,65 Kimberly R. Kalli,66 Beth Y. Karlan,67 Stanley B. Kaye,68 Linda E. Kelemen,69 Lambertus A. Kiemeney,7,8,70 Fumitaka Kikkawa,71 Gottfried E. Konecny,47 Camilla Krakstad,57,58 Susanne Kruger Kjaer,61,63 Jolanta Kupryjanczyk,37 Diether Lambrechts,72,73 Sandrina Lambrechts,38 Johnathan M. Lancaster,52 Nhu D. Le,74 Arto Leminen,26 Douglas A. Levine,75 Dong Liang,76 Boon Kiong Lim,77 Jie Lin,78 Jolanta Lissowska,79 Karen H. Lu,80 Jan Lubiński,55 Galina Lurie,81 Leon F.A.G. Massuger,82 Keitaro Matsuo,64 Valerie McGuire,83 John R McLaughlin,84,85 Usha Menon,49 Francesmary Modugno,78,80,86 Kirsten B. Moysich,87 Toru Nakanishi,88 Steven A. Narod,89 Lotte Nedergaard,90 Roberta B. Ness,91 Heli Nevanlinna,26 Stefan Nickels,29 Houtan Noushmehr,32,92 Kunle Odunsi,93 Sara H. Olson,94 Irene Orlow,94 James Paul,51 Celeste L Pearce,2 Tanja Pejovic,95,96 Liisa M. Pelttari,26 Malcolm C. Pike,2,94 Elizabeth M. Poole,97,98 Paola Raska,18 Stefan P. Renner,19 Harvey A. Risch,99 Lorna Rodriguez-Rodriguez,17 Mary Anne Rossing,100,101 Anja Rudolph,29 Ingo B. Runnebaum,42 Iwona K. Rzepecka,37 Helga B. Salvesen,57,58 Ira Schwaab,102 Gianluca Severi,15,16 Vijayalakshmi Shridhar,103 Xiao-Ou Shu,27 Yurii B. Shvetsov,81 Weiva Sieh,83 Honglin Song,3 Melissa C. Southey,104 Beata Spiewankiewicz,105 Daniel Stram,2 Rebecca Sutphen,106 Soo-Hwang Teo,77 Kathryn L. Terry,36 Daniel C. Tessier,14 Pamela J. Thompson,53 Shelley S. Tworoger,97,98 Anne M. van Altena,82 Ignace Vergote,38 Robert A. Vierkant,31 Daniel Vincent,14 Allison F. Vitonis,36 Shan Wang-Gohrke,107 Rachel Palmieri Weber,108 Nicolas Wentzensen,22 Alice S. Whittemore,83 Elisabeth Wik,57,58 Lynne R. Wilkens,81 Boris Winterhoff,109 Yin Ling Woo,77 Anna H. Wu,2 Yong-Bing Xiang,110 Hannah P. Yang,22 Wei Zheng,27 Argyrios Ziogas,111 Famida Zulkifli,77 Catherine M. Phelan,1 Edwin Iversen,112 Joellen M. Schildkraut,108,113 Andrew Berchuck,114 Brooke L. Fridley,115 Ellen L. Goode,31 Paul D. P. Pharoah,11,43 Alvaro N.A. Monteiro,1 Thomas A. Sellers,1 and Simon A. Gayther2

Publish date

2013 Jul 12.




The purpose of this study was to identify differences in both demographic and pathologic factors associated with the age-related rates of colorectal cancer (CRC) and overall survival (OS).

The National Cancer Data Base (NCDB), 2004-2013, was queried for patients with CRC. Patients were stratified by age (≤50 vs. ≥60 years). Multivariable analysis was performed to identify factors associated with OS.

A total of 670,030 patients were included; 488,121 with colon, and 181,909 with rectal or rectosigmoid cancer. For colon cancer, patients ≤50 years had higher proportions of pathologic stage III and IV disease than patients ≥60 (III: 33.7% vs. 28.6%, IV: 25.5% vs. 14.3%, respectively; P≤0.001). Similar differences were found for patients with rectal cancer (III: 35.8% vs. 28.6%, IV: 16.5% vs. 11.6%, respectively for age ≤50 and ≥60 years; P≤0.001). More aggressive pathologic factors were identified in the ≤50 cohort and were associated with worse OS, including higher tumor grade, lymphovascular invasion (LVI), perineural invasion (PNI), and elevated serum carcinoembryonic antigen (CEA). Disparities associated with OS were also identified for both colon and rectal cancer. For patients ≤50 with CRC, African-American and Hispanic race, lower income and lower education were associated with increased risk of mortality compared to the ≥60 cohort.

There are clear differences in biological factors and in racial and socioeconomic disparities of patients with early onset CRC. Earlier screening should be seriously considered in patients under 50 years who are African-American and Hispanic, as these populations present with more aggressive and advanced disease.


Colorectal cancer (CRC), early onset, National Cancer Data Base (NCDB)


Age-related rates of colorectal cancer and the factors associated with overall survival


Emmanuel Gabriel,1 Kristopher Attwood,2 Eisar Al-Sukhni,3 Deborah Erwin,4 Patrick Boland,5 and Steven Nurkincorresponding author3

Publish date

2018 Feb;




Ovarian cancer (OC) accounts for more deaths than all other gynecological cancers combined. To identify common low-penetrance OC susceptibility genes, we conducted a genome-wide association study (GWAS) of 507,094 SNPs in 1,768 cases and 2,354 controls, with follow-up of 21,955 SNPs in 4,162 cases and 4,810 controls, leading to the identification of a confirmed susceptibility locus at 9p22 (BNC2)1. Here, we report on nine additional candidate loci (p≤10-4), identified after stratifying cases by histology, genotyped in an additional 4,353 cases and 6,021 controls. Two novel susceptibility loci with p≤5×10-8 were confirmed (8q24, p=8.0×10-15 and 2q31, p=3.8×10-14); two additional loci were also identified that approached genome-wide significance (3q25, p=7.1×10-8 and 17q21, p=1.4×10-7). The associations with serous OC were generally stronger than other subtypes. Analysis of HOXD1, MYC, TiPARP, and SKAP1 at these loci, and BNC2 at 9p22, supports a functional role for these genes in OC development.


A Genome-Wide Association Study Identifies Susceptibility Loci for Ovarian Cancer at 2q31 and 8q24


Ellen L. Goode,1,*# Georgia Chenevix-Trench,2,* Honglin Song,3,* Susan J. Ramus,4,* Maria Notaridou,4 Kate Lawrenson,4 Martin Widschwendter,4 Robert A. Vierkant,1 Melissa C. Larson,1 Susanne K. Kjaer,5 Michael J. Birrer,6 Andrew Berchuck,7 Joellen Schildkraut,7 Ian Tomlinson,8 Lambertus A. Kiemeney,9 Linda S. Cook,10 Jacek Gronwald,11 Montserrat Garcia-Closas,12 Martin E. Gore,13 Ian Campbell,14 Alice S. Whittemore,15 Rebecca Sutphen,16 Catherine Phelan,17 Hoda Anton-Culver,18 Celeste Leigh Pearce,19 Diether Lambrechts,20 Mary Anne Rossing,21 Jenny Chang-Claude,22 Kirsten B. Moysich,23 Marc T. Goodman,24 Thilo Dork,25 Heli Nevanlinna,26 Roberta B. Ness,27 Thorunn Rafnar,28 Claus Hogdall,29 Estrid Hogdall,30 Brooke L. Fridley,1 Julie M. Cunningham,31 Weiva Sieh,16 Valerie McGuire,16 Andrew K. Godwin,32 Daniel W. Cramer,33 Dena Hernandez,34 Douglas Levine,35 Karen Lu,36 Edwin S. Iversen,37 Rachel T. Palmieri,38 Richard Houlston,39 Anne M. van Altena,40 Katja K.H. Aben,41 Leon F.A.G. Massuger,40 Angela Brooks-Wilson,42 Linda E. Kelemen,43 Nhu D. Le,44 Anna Jakubowska,11 Jan Lubinski,11 Krzysztof Medrek,11 Anne Stafford,3 Douglas F. Easton,45 Jonathan Tyrer,3 Kelly L. Bolton,46 Patricia Harrington,3 Diana Eccles,47 Ann Chen,17 Ashley N. Molina,15 Barbara N. Davila,15 Hector Arango,48 Ya-Yu Tsai,17 Zhihua Chen,17 Harvey A. Risch,49 John McLaughlin,50 Steven A. Narod,51 Argyrios Ziogas,18 Wendy Brewster,52 Aleksandra Gentry-Maharaj,4 Usha Menon,4 Anna H. Wu,19 Daniel O. Stram,19 Malcolm C. Pike,19 The Wellcome Trust Case-Control Consortium,53 Jonathan Beesley,2 Penelope M. Webb,2 The Australian Cancer Study (Ovarian Cancer),2 The Australian Ovarian Cancer Study Group,54 Xiaoqing Chen,2 Arif B. Ekici,55 Falk C. Thiel,56 Matthias W. Beckmann,57 Hannah Yang,12 Nicolas Wentzensen,12 Jolanta Lissowska,57 Peter A. Fasching,58 Evelyn Despierre,59 Frederic Amant,59 Ignace Vergote,59 Jennifer Doherty,21 Rebecca Hein,22 Shan Wang-Gohrke,60 Galina Lurie,24 Michael E. Carney,24 Pamela J. Thompson,24 Ingo Runnebaum,5 Peter Hillemanns,25 Matthias Durst,61 Natalia Antonenkova,62 Natalia Bogdanova,63 Arto Leminen,26 Ralf Butzow,64 Tuomas Heikkinen,26 Kari Stefansson,28 Patrick Sulem,28 Soren Besenbacher,28 Thomas A. Sellers,17 Simon A. Gayther,4 and Paul D.P. Pharoah65, on behalf of the Ovarian Cancer Association Consortium (OCAC)

Publish date

2011 Oct 1.